Highlights from the 4th Annual CCA Summit



December 2022, Vol 3, No 4 — December 22, 2022
A multidisciplinary approach to treating localized disease in cholangiocarcinoma (CCA) is important, and management strategies for advanced disease have the potential to be used in patients who undergo surgical resection.
Read More

December 2022, Vol 3, No 4 — December 22, 2022
Improving early return to function and minimizing complications are important considerations for patients with resectable cholangiocarcinoma (CCA), but data on minimally invasive liver surgery have been limited to single or multi-institutional retrospective studies. Of note, 2 randomized studies have shown that laparoscopic removal of colorectal liver metastases improved outcomes in complication rates, length of stay, and pain burden without compromising margin status compared with open surgery.
Read More

December 2022, Vol 3, No 4 — December 22, 2022
Historically, liver transplantation in patients with cholangiocarcinoma (CCA) was considered a contraindication at most US medical centers; however, with recent advances, the United Network for Organ Sharing (UNOS) liver intestine committee now recognizes that transplantation is indicated in hilar CCA when performed under institutional protocols with neoadjuvant chemoradiation. Maria Majella Doyle, MD, MBA, of Washington University School of Medicine and Mid America Transplant Services, discussed liver transplant in her presentation, detailing protocols and efficacy results from the Mayo Clinic and other centers in hilar CCA and beyond.
Read More

December 2022, Vol 3, No 4 — December 22, 2022
Systemic control has always been the mainstay in the treatment of advanced biliary tract cancer (BTC), with several first- and second-line therapies approved by the US Food and Drug Administration.
Read More

December 2022, Vol 3, No 4 — December 22, 2022
Teresa Macarulla, MD, PhD, of the Vall d’Hebron University Hospital in Barcelona, Spain, and Mark Yarchoan, MD, from Johns Hopkins Medicine, debated the question, “Should immunotherapy be standard of care in cholangiocarcinoma (CCA)?”
Read More

December 2022, Vol 3, No 4 — December 22, 2022
Milind Javle, MD, of the MD Anderson Cancer Center, led off the roundtable dialogue on emerging therapies in biliary tract cancers (BTCs) with a discussion around methylthioadenosine phosphorylase (MTAP) loss in cholangiocarcinoma (CCA). MTAP is located on the 9p21 chromosome, where CDKN2A/B is also located.
Read More

December 2022, Vol 3, No 4 — December 22, 2022
Mark Schattner, MD, FASGE, AGAF, of Memorial Sloan Kettering Cancer Center, discussed endoscopic biliary drainage (EBD) in cholangiocarcinoma (CCA), specifically in hilar obstruction, emphasizing the different goals and techniques in patients with resectable versus unresectable disease. The ultimate goals for management of obstruction in patients with resectable CCA are to optimize them for surgery and avoid perioperative complications and unnecessary procedures.
Read More


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: